查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1607225

Guillain-Barré二氏症候群市场：按类型、治疗方法和最终用户划分 - 全球预测 2025-2030

Guillain-Barre Syndrome Market by Type, Treatment, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年Guillain-Barré二氏症候群市场价值为6.3443亿美元，预计到2024年将达到6.6539亿美元，复合年增长率为2.10%，预计到2030年将达到7.3424亿美元。

Guillain-Barré二氏症候群(GBS) 是一种急性免疫介导的疾病，会影响週边神经系统，导致快速进行性虚弱和潜在的瘫痪。作为 360iResearch 的市场研究分析师，了解 GBS 相关医疗介入和治疗的范围、需求和使用至关重要。 GBS主要需求于神经科科诊所、医院和復健中心，因为它需要快速的医疗诊断、免疫治疗和復健服务。随着全球盛行率的上升、认识的提高和诊断技术的增强，GBS 市场有望成长。关键的成长要素包括支持性护理的进步以及静脉注射免疫球蛋白和血浆置换等治疗解决方案的进步。製药公司增加医疗保健投资和新疗法的研究经费也将推动市场向前发展。此外，更容易患自体免疫疾病的人口老化正在推动需求。然而，该市场面临局限性，包括治疗成本高、准确诊断GBS的复杂性以及由于症状与其他神经系统疾病的相似性而存在误诊的风险。监管挑战和新疗法严格的核准流程构成了障碍，使市场扩张更加复杂。儘管存在这些挑战，但开发旨在超越当前治疗方法的创新疗法的机会仍然存在。个人化医疗、再生疗法和基因组解决方案等新兴领域为差异化和成长提供了令人兴奋的前景。此外，利用人工智慧和机器学习进行准确的早期诊断有可能彻底改变患者的治疗结果并提供长期的商机。最后，学术机构和医疗保健公司之间合作进行临床试验和研究可以促进创新。因此，对于想要在不断发展的 GBS 市场中建立据点的公司来说，强调强大的研发、策略伙伴关係和高效的医疗保健服务系统至关重要。

主要市场统计
基准年[2023] 63443万美元
预计年份 [2024] 66539万美元
预测年份 [2030] 7.3424亿美元
复合年增长率（%） 2.10%

市场动态：针对快速发展的Guillain-Barré二氏症候群市场揭示的关键市场洞察

供需的动态交互作用正在改变Guillain-Barré二氏症候群市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • Guillain-Barré二氏症候群在全球的盛行率不断扩大
    • 扩大静脉注射免疫球蛋白注射治疗Guillain-Barré二氏症候群的应用
    • 提高消费者的医疗保健意识和支出
  • 市场限制因素
    • 治疗和药物费用上涨
  • 市场机会
    • Guillain-Barré二氏症候群的治疗进展
    • 罕见疾病政府优惠报销政策
  • 市场挑战
    • 疾病诊治意识淡薄

波特的五力：驾驭Guillain-Barré二氏症候群市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解Guillain-Barré二氏症候群市场的外部影响

外部宏观环境因素在塑造Guillain-Barré二氏症候群市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解Guillain-Barré二氏症候群市场的竞争状况

对Guillain-Barré二氏症候群市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵Guillain-Barré二氏症候群市场供应商的绩效评估

FPNV 定位矩阵是评估Guillain-Barré二氏症候群市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了Guillain-Barré二氏症候群市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对Guillain-Barré二氏症候群市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界范围Guillain-Barré二氏症候群的盛行率增加
      • 静脉注射免疫球蛋白扩大用于治疗Guillain-Barré二氏症候群
      • 提高消费者的医疗保健意识和支出
    • 抑制因素
      • 治疗和药物费用上涨
    • 机会
      • Guillain-Barré二氏症候群的治疗进展
      • 罕见疾病政府优惠报销政策
    • 任务
      • 疾病诊治意识淡薄
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章Guillain-Barré二氏症候群市场：依类型

  • 急性发炎去髓鞘化神经炎
  • 急性运动/感觉轴突神经病变
  • 急性运动轴突神经病变
  • 米勒-费雪综合症

第七章Guillain-Barré二氏症候群治疗市场

  • 水疗
  • 药物治疗
  • 物理治疗
  • 血浆置换

第八章Guillain-Barré二氏症候群市场：依最终用户分类

  • 诊断中心
  • 医院

第九章 美洲Guillain-Barré二氏症候群市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区Guillain-Barré二氏症候群市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东与非洲Guillain-Barré二氏症候群市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Akari Therapeutics Plc
  • Annexon Inc.
  • Cellenkos Inc.
  • CSL Limited
  • CuraVac Europe SA
  • Electrical Geodesics Inc.
  • Grifols SA
  • Hansa Biopharma
  • Kedrion Biopharma Inc.
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-450A0628D980

The Guillain-Barre Syndrome Market was valued at USD 634.43 million in 2023, expected to reach USD 665.39 million in 2024, and is projected to grow at a CAGR of 2.10%, to USD 734.24 million by 2030.

Guillain-Barre Syndrome (GBS) is an acute, immune-mediated disorder affecting the peripheral nervous system, leading to rapidly progressing weakness and potential paralysis. As a market research analyst at 360iResearch, it is vital to understand the scope, necessity, and applications of GBS-related medical interventions and treatments. GBS primarily requires rapid medical diagnosis, immunotherapy, and rehabilitation services, leading to growing demand in neurology clinics, hospitals, and rehabilitation centers. With an increasing incidence rate globally, attributed to rising awareness and enhanced diagnostic techniques, the GBS market is poised for growth. Key growth factors include advancements in therapeutic solutions, such as intravenous immunoglobulins and plasmapheresis, alongside advancements in supportive care. Increasing healthcare investment and research funding for novel therapies by pharmaceutical companies also propel the market forward, while the aging population, more prone to autoimmune disorders, drives demand. However, the market faces limitations, including high costs associated with treatment and the complexity of accurately diagnosing GBS, compounded by a threat of misdiagnosis due to symptom similarity with other neurological disorders. Regulatory challenges and stringent approval processes for new therapies present hurdles, further complicating market expansion. Despite these challenges, opportunities abound in the development of innovative therapeutics aimed at advancing beyond current treatment regimens. Emerging areas such as personalized medicine, regenerative therapy, and genomic solutions offer exciting prospects for differentiation and growth. Additionally, leveraging AI and machine learning for accurate early diagnosis could revolutionize patient outcomes, offering long-term business opportunities. Lastly, collaboration between academic institutions and healthcare companies to conduct clinical trials and research can drive innovation. Therefore, an emphasis on robust R&D, strategic partnerships, and efficient healthcare delivery systems will be crucial for companies aiming to establish a stronghold in the evolving GBS market.

KEY MARKET STATISTICS
Base Year [2023] USD 634.43 million
Estimated Year [2024] USD 665.39 million
Forecast Year [2030] USD 734.24 million
CAGR (%) 2.10%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Guillain-Barre Syndrome Market

The Guillain-Barre Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of Guillain-Barre syndrome worldwide
    • Growing adoption of intravenous immunoglobulins for treatment of Guillain-Barre syndrome
    • Rising consumer healthcare awareness and expenditures
  • Market Restraints
    • High costs of treatment and drugs
  • Market Opportunities
    • Advances in management of Guillain-Barre syndrome
    • Favorable governmental reimbursement policies for rare diseases
  • Market Challenges
    • Less awareness towards disease diagnosis and treatment

Porter's Five Forces: A Strategic Tool for Navigating the Guillain-Barre Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Guillain-Barre Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Guillain-Barre Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Guillain-Barre Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Guillain-Barre Syndrome Market

A detailed market share analysis in the Guillain-Barre Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Guillain-Barre Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Guillain-Barre Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Guillain-Barre Syndrome Market

A strategic analysis of the Guillain-Barre Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Guillain-Barre Syndrome Market, highlighting leading vendors and their innovative profiles. These include Akari Therapeutics Plc, Annexon Inc., Cellenkos Inc., CSL Limited, CuraVac Europe S.A., Electrical Geodesics Inc., Grifols S.A., Hansa Biopharma, Kedrion Biopharma Inc., Octapharma AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Guillain-Barre Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Acute Inflammatory Demyelinating Polyneuropathy, Acute Motor & Sensory Axonal Neuropathy, Acute Motor Axonal Neuropathy, and Miller Fisher Syndrome.
  • Based on Treatment, market is studied across Hydrotherapy, Medication, Physical Therapy, and Plasmapheresis.
  • Based on End-User, market is studied across Diagnostic Centers and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of Guillain-Barre syndrome worldwide
      • 5.1.1.2. Growing adoption of intravenous immunoglobulins for treatment of Guillain-Barre syndrome
      • 5.1.1.3. Rising consumer healthcare awareness and expenditures
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of treatment and drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Advances in management of Guillain-Barre syndrome
      • 5.1.3.2. Favorable governmental reimbursement policies for rare diseases
    • 5.1.4. Challenges
      • 5.1.4.1. Less awareness towards disease diagnosis and treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Guillain-Barre Syndrome Market, by Type

  • 6.1. Introduction
  • 6.2. Acute Inflammatory Demyelinating Polyneuropathy
  • 6.3. Acute Motor & Sensory Axonal Neuropathy
  • 6.4. Acute Motor Axonal Neuropathy
  • 6.5. Miller Fisher Syndrome

7. Guillain-Barre Syndrome Market, by Treatment

  • 7.1. Introduction
  • 7.2. Hydrotherapy
  • 7.3. Medication
  • 7.4. Physical Therapy
  • 7.5. Plasmapheresis

8. Guillain-Barre Syndrome Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Hospitals

9. Americas Guillain-Barre Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Guillain-Barre Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Guillain-Barre Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Akari Therapeutics Plc
  • 2. Annexon Inc.
  • 3. Cellenkos Inc.
  • 4. CSL Limited
  • 5. CuraVac Europe S.A.
  • 6. Electrical Geodesics Inc.
  • 7. Grifols S.A.
  • 8. Hansa Biopharma
  • 9. Kedrion Biopharma Inc.
  • 10. Octapharma AG
  • 11. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GUILLAIN-BARRE SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. GUILLAIN-BARRE SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GUILLAIN-BARRE SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GUILLAIN-BARRE SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR & SENSORY AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY ACUTE MOTOR AXONAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MILLER FISHER SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY PLASMAPHERESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM GUILLAIN-BARRE SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. GUILLAIN-BARRE SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. GUILLAIN-BARRE SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023